



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/199537/2016

European Medicines Agency decision

P/0106/2016

of 15 April 2016

on the acceptance of a modification of an agreed paediatric investigation plan for potassium citrate monohydrated / potassium hydrogen carbonate (EMEA-001357-PIP01-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0106/2016

of 15 April 2016

on the acceptance of a modification of an agreed paediatric investigation plan for potassium citrate monohydrated / potassium hydrogen carbonate (EMA-001357-PIP01-12-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0257/2014 issued on 1 October 2014,

Having regard to the application submitted by Advicenne Pharma on 7 December 2015 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 February 2016, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for potassium citrate monohydrated / potassium hydrogen carbonate, prolonged-release granules, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Advicenne Pharma, 2, rue Briçonnet, 30000 – Nîmes, France.

Done at London, 15 April 2016

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/858773/2015
London, 26 February 2016

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001357-PIP01-12-M01

Scope of the application

Active substance(s):

Potassium citrate monohydrated / Potassium hydrogen carbonate

Condition(s):

Treatment of renal tubular acidosis

Pharmaceutical form(s):

Prolonged-release granules

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Advicenne Pharma

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Advicenne Pharma submitted to the European Medicines Agency on 7 December 2015 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0257/2014 issued on 1 October 2014.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral. .

The procedure started on 4 January 2016.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of renal tubular acidosis

The waiver applies to:

- The paediatric population from birth to less than 6 months of age;
- for prolonged-release granules for oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition:

Treatment of renal tubular acidosis

2.1.1. Indication(s) targeted by the PIP

Treatment of distal renal tubular acidosis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Prolonged-release granules

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Compatibility study of Potassium citrate monohydrated / Potassium hydrogen carbonate prolonged-release granules with food.
Non-clinical studies	0	Not applicable.
Clinical studies	2	Study 2 Multicentre, open-label, non-inferiority, sequential study to evaluate the relative efficacy of Potassium citrate monohydrated / Potassium hydrogen carbonate prolonged-release granules and standard of care (SoC) on correcting metabolic acidosis (B21CS).

Area	Number of measures	Description
		Study 3 Multicentre, open-label extension study to evaluate the safety and tolerability of Potassium citrate monohydrated / Potassium hydrogen carbonate prolonged-release granules in subjects presenting a distal renal tubular acidosis (B22CS).
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By April 2018
Deferral for one or more measures contained in the paediatric investigation plan:	Yes